News Quantified

APRE – aprea therapeutics, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical Advisor

Aprea Therapeutics (NASDAQ:APRE) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock, down previously from $5.00.

Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First Scan

Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Aprea Therapeutics (NASDAQ:APRE) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.

Form 4 Aprea Therapeutics, Inc. For: Jan 30 Filed by: Gilad Oren

Form 4 Aprea Therapeutics, Inc. For: Jan 30 Filed by: Hamill John P.

Form 8-K Aprea Therapeutics, Inc. For: Jan 28

Form SCHEDULE 13G/A Aprea Therapeutics, Inc. Filed by: HIRSCHMAN ORIN

Form 8-K Aprea Therapeutics, Inc. For: Jan 23

Top News Gainers

10/2 Form 3 Aprea Therapeutics, Inc. For: Oct 02 Filed by: Coiante Scott M 32.6%

11/14 Aprea Therapeutics (NASDAQ: APRE) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. 10.6%

12/12 Recap and Update of Positive Data from Phase Ib/II Clinical Trials of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2019 American Society of Hematology (ASH) An 9.3%

3/27 Aprea Therapeutics (NASDAQ: APRE) had its "hold" rating re-affirmed by analysts at Morgan Stanley. They now have a $36.00 price target on the stock. 9.1%

4/3 Form 8-K Aprea Therapeutics, Inc. For: Apr 03 6.5%

10/7 U.S. IPO Weekly Recap: Oncology Biotech Aprea Therapeutics Finishes On Top In 4-IPO Week [Seeking Alpha] 6.2%

10/17 Form SC 13D Aprea Therapeutics, Inc. Filed by: 5AM Ventures IV, L.P. 4.5%

1/13 Form 8-K Aprea Therapeutics, Inc. For: Jan 13 3.6%

10/9 Form 4 Aprea Therapeutics, Inc. For: Oct 07 Filed by: Schwab Andrew J. 2.1%

11/18 Form S-8 Aprea Therapeutics, Inc. 2.0%

Top News Decliners

3/26 Q4/2019 12/31/2019 EPS -0.640 ZacksConsensus -0.390 ActVsEst (0.250) - Miss -11.5%

10/4 Form 424B4 Aprea Therapeutics, Inc. -8.7%

12/9 Aprea Therapeutics Presents Results From U.S. Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual -7.7%

10/7 Form 4 Aprea Therapeutics, Inc. For: Oct 07 Filed by: Seizinger Bernd R. -7.6%

4/29 Form DEFA14A Aprea Therapeutics, Inc. -5.6%

2/14 Form SC 13G Aprea Therapeutics, Inc. Filed by: KDev Investments AB -4.6%

2/13 Aprea Therapeutics Appoints Gregory S. Wessels as Vice President, Commercial -4.1%

10/28 Aprea Therapeutics (NASDAQ: APRE) is now covered by analysts at JPMorgan Chase & Co.. They set a "neutral" rating on the stock. -2.8%

11/12 Form SC 13G Aprea Therapeutics, Inc. Filed by: FMR LLC -2.4%

1/9 Aprea Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020 -2.1%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day